A phase II study of olaparib monotherapy in patients with various metastatic malignancies and germline BRCA1/BRCA2 mutations included 23 patients with pancreatic adenocarcinoma [56]. The gene discussed is BRCA2; the disease is pancreatic adenocarcinoma.